Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

kodiak sciences inc - KOD

KOD

Close Chg Chg %
85.78 1.85 2.16%

Closed Market

87.63

+1.85 (2.16%)

Volume: 526.95K

Last Updated:

Oct 23, 2026, 4:00 PM EDT

Trade Now

Company Overview: kodiak sciences inc - KOD

KOD Key Data

Open

$85.13

 Day Range

83.16 - 87.85

52 Week Range

15.83 - 104.00

 Market Cap

$5.51B

Shares Outstanding

62.85M

 Public Float

57.48M

Beta

2.04

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.19

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

3.66M

  

KOD Performance

1 Week
 
 2.19%
 
1 Month
 
 170.88%
 
3 Months
 
 111.62%
 
1 Year
 
 368.86%
 
5 Years
 
 -24.46%
 

KOD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About kodiak sciences inc - KOD

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

KOD At a Glance

Kodiak Sciences, Inc.
1250 Page Mill Road
Palo Alto, California 94304
Phone 1-650-281-0850 Revenue 0.00
Industry Biotechnology Net Income -229,967,000.00
Sector Health Technology Employees 124
Fiscal Year-end 12 / 2026
View SEC Filings

KOD Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 10.972
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -6.97
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.111

KOD Efficiency

Revenue/Employee N/A
Income Per Employee -1,854,572.581
Receivables Turnover N/A
Total Asset Turnover N/A

KOD Liquidity

Current Ratio 4.718
Quick Ratio 4.718
Cash Ratio 4.609

KOD Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -66.937
Return on Equity -149.489
Return on Total Capital -72.645
Return on Invested Capital -74.846

KOD Capital Structure

Total Debt to Total Equity 101.142
Total Debt to Total Capital 50.284
Total Debt to Total Assets 45.282
Long-Term Debt to Equity 93.477
Long-Term Debt to Total Capital 46.473
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Kodiak Sciences Inc - KOD

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
11.00M 25.95M 26.71M 26.32M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
11.00M 25.95M 26.71M 26.32M
Depreciation
11.00M 25.95M 26.71M 26.32M
Amortization of Intangibles
- - - -
-
COGS Growth
+26.29% +135.86% +2.93% -1.45%
Gross Income
(11.00M) (25.95M) (26.71M) (26.32M)
Gross Income Growth
-26.29% -135.86% -2.93% +1.45%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
330.38M 251.37M 160.14M 206.16M
Research & Development
267.59M 206.30M 126.09M 182.37M
Other SG&A
62.79M 45.08M 34.05M 23.79M
SGA Growth
+27.88% -23.91% -36.29% +28.73%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 1.91M
-
EBIT after Unusual Expense
(341.38M) (277.32M) (186.85M) (234.39M)
Non Operating Income/Expense
7.57M 16.84M 10.64M 4.42M
Non-Operating Interest Income
7.07M 16.73M 11.15M 4.52M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 18.00K 13.00K
-
Interest Expense Growth
- - -18.18% -27.78%
-
Gross Interest Expense
- - 18.00K 13.00K
-
Interest Capitalized
- - - -
-
Pretax Income
(333.82M) (260.49M) (176.21M) (229.97M)
Pretax Income Growth
-25.03% +21.97% +32.36% -30.51%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(333.82M) (260.49M) (176.21M) (229.97M)
Minority Interest Expense
- - - -
-
Net Income
(333.82M) (260.49M) (176.21M) (229.97M)
Net Income Growth
-25.03% +21.97% +32.36% -30.51%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(333.82M) (260.49M) (176.21M) (229.97M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(333.82M) (260.49M) (176.21M) (229.97M)
EPS (Basic)
-6.389 -4.9698 -3.351 -4.322
EPS (Basic) Growth
-23.93% +22.21% +32.57% -28.98%
Basic Shares Outstanding
52.25M 52.41M 52.58M 53.21M
EPS (Diluted)
-6.389 -4.9698 -3.351 -4.322
EPS (Diluted) Growth
-23.93% +22.21% +32.57% -28.98%
Diluted Shares Outstanding
52.25M 52.41M 52.58M 53.21M
EBITDA
(330.38M) (251.37M) (160.14M) (206.16M)
EBITDA Growth
-27.88% +23.91% +36.29% -28.73%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 116.667
Number of Ratings 6 Current Quarters Estimate -1.03
FY Report Date 12 / 2026 Current Year's Estimate -4.079
Last Quarter’s Earnings -1.045 Median PE on CY Estimate N/A
Year Ago Earnings -4.32 Next Fiscal Year Estimate -3.85
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 2 6 5
Mean Estimate -1.03 -1.24 -4.08 -3.85
High Estimates -0.89 -1.16 -3.75 -1.99
Low Estimate -1.26 -1.32 -4.57 -5.51
Coefficient of Variance -13.31 -9.12 -6.93 -36.14

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 5
OVERWEIGHT 0 0 0
HOLD 1 1 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Kodiak Sciences Inc - KOD

Date Name Shares Transaction Value
Oct 1, 2026 Baker Bros. Advisors LP Director 18,373,116 Open market or private purchase of non-derivative security Non-derivative transaction at $61.21 per share 1,124,618,430.36
Oct 1, 2026 Baker Bros. Advisors LP Director 18,852,329 Open market or private purchase of non-derivative security Non-derivative transaction at $73.08 per share 1,377,728,203.32
Oct 1, 2026 Baker Bros. Advisors LP Director 1,589,857 Open market or private purchase of non-derivative security Non-derivative transaction at $73.08 per share 116,186,749.56
Oct 1, 2026 Baker Bros. Advisors LP Director 18,773,603 Open market or private purchase of non-derivative security Non-derivative transaction at $72.39 per share 1,359,021,121.17
Oct 1, 2026 Baker Bros. Advisors LP Director 1,585,161 Open market or private purchase of non-derivative security Non-derivative transaction at $72.39 per share 114,749,804.79
Oct 1, 2026 Baker Bros. Advisors LP Director 18,494,625 Open market or private purchase of non-derivative security Non-derivative transaction at $71.48 per share 1,321,995,795.00
Oct 1, 2026 Baker Bros. Advisors LP Director 1,568,520 Open market or private purchase of non-derivative security Non-derivative transaction at $71.48 per share 112,117,809.60
Oct 1, 2026 Baker Bros. Advisors LP Director 18,476,927 Open market or private purchase of non-derivative security Non-derivative transaction at $68.96 per share 1,274,168,885.92
Oct 1, 2026 Baker Bros. Advisors LP Director 1,567,464 Open market or private purchase of non-derivative security Non-derivative transaction at $68.96 per share 108,092,317.44
Oct 1, 2026 Baker Bros. Advisors LP Director 18,437,861 Open market or private purchase of non-derivative security Non-derivative transaction at $68.37 per share 1,260,596,556.57
Oct 1, 2026 Baker Bros. Advisors LP Director 1,565,133 Open market or private purchase of non-derivative security Non-derivative transaction at $68.37 per share 107,008,143.21
Oct 1, 2026 Baker Bros. Advisors LP Director 18,435,276 Open market or private purchase of non-derivative security Non-derivative transaction at $67.1 per share 1,237,007,019.60
Oct 1, 2026 Baker Bros. Advisors LP Director 1,564,979 Open market or private purchase of non-derivative security Non-derivative transaction at $67.1 per share 105,010,090.90
Oct 1, 2026 Baker Bros. Advisors LP Director 18,429,894 Open market or private purchase of non-derivative security Non-derivative transaction at $64.43 per share 1,187,438,070.42
Oct 1, 2026 Baker Bros. Advisors LP Director 1,564,658 Open market or private purchase of non-derivative security Non-derivative transaction at $64.43 per share 100,810,914.94
Oct 1, 2026 Baker Bros. Advisors LP Director 18,421,873 Open market or private purchase of non-derivative security Non-derivative transaction at $62.96 per share 1,159,841,124.08
Oct 1, 2026 Baker Bros. Advisors LP Director 1,564,179 Open market or private purchase of non-derivative security Non-derivative transaction at $62.96 per share 98,480,709.84
Oct 1, 2026 Baker Bros. Advisors LP Director 18,417,806 Open market or private purchase of non-derivative security Non-derivative transaction at $61.63 per share 1,135,089,383.78
Oct 1, 2026 Baker Bros. Advisors LP Director 1,563,936 Open market or private purchase of non-derivative security Non-derivative transaction at $61.63 per share 96,385,375.68
Oct 1, 2026 Baker Bros. Advisors LP Director 1,561,270 Open market or private purchase of non-derivative security Non-derivative transaction at $61.21 per share 95,565,336.70

Kodiak Sciences Inc in the News